Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Rhea-AI Summary
Nutriband (NASDAQ:NTRB) has announced key dates for its upcoming 25% preferred stock dividend. Shareholders of record as of July 25th, 2025 will receive one preferred share for every four common shares held, with the distribution set for August 5th.
The preferred shares come with two key features: they will be convertible to common stock upon FDA approval of the company's AVERSA Fentanyl product, and if not converted, shareholders will be entitled to an annual cash dividend from company profits, as determined by the Board of Directors.
Positive
- None.
Negative
- Preferred share conversion dependent on uncertain FDA approval timing
- Cash dividend amount not specified and subject to board discretion
- Dividend payment contingent on company achieving profits
News Market Reaction – NTRB
On the day this news was published, NTRB gained 4.51%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $95M at that time.
Data tracked by StockTitan Argus on the day of publication.
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) is today reminding shareholders of the key dates associated with its upcoming
Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th.
Each preferred share will be convertible to one share of common stock following FDA approval of the Company’s AVERSA Fentanyl product.
If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
When is the record date for Nutriband's (NTRB) preferred stock dividend?
What is the pay date for NTRB's preferred stock dividend?
How can Nutriband (NTRB) preferred shares be converted to common stock?
What happens if NTRB preferred shares are not converted?
What is the conversion ratio for Nutriband's preferred stock dividend?
